SEC Form 4 · accession 0001358403-17-000015
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Farrell
Officer — President and CEO · Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 7:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $13.89 | Jan 3, 2017 | A | 48,375 | A | — | Jan 2, 2027 | Common Stock | 48,375 | 48,375 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 3, 2017 | A | 26,875 | A | — | — | Common Stock | 26,875 | 26,875 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 3, 2018.